NCT00192452已完成2 期
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of MEDI-507, a Humanized Monoclonal Antibody That Binds to the CD2 Receptor, Administered by Intravenous Infusion to Adults With Plaque Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 3
- 主要终点
- Analyses of categorical data will be performed and analysis of continuous data will be performed using a one-way analysis of variance (ANOVA) with traetment group as a factor.
研究概览
简要总结
- The primary objective of this study is to compare disease activity, as measured by PASI score, of two MEDI-507 dose levels (0.012 and 0.04 mg/kg) versus placebo administered by intravenous infusion every 2 weeks for a total of 8 infusions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Plaque psoriasis involving at least 10% of body surface area (Appendix B)
- •Age 18 through 65 years at the time of the first dose of study drug
- •Both males and females are eligible. However, sexually active females, unless surgically sterile or at least 1 year post-menopausal, must have used an effective method of avoiding pregnancy (including oral or implanted contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 30 days prior to the first dose of study drug and must agree to continue using such precautions for 60 days after the final dose of study drug
- •Currently receiving no therapy for psoriasis except emollients (certain other over-the-counter products may be allowed with prior approval of the sponsor)
- •Written informed consent obtained from the patient
- •Ability to complete follow-up period of 188 days as required by the protocol
排除标准
- •Pustular, guttate, or erythrodermic psoriasis as the predominant disease type
- •PASI score <8
- •At screening (must be within 21 days before study entry) any of the following: lymphocyte count under 1,200 cells/mm3, WBC under 4,000 cells/mm3, hematocrit below 32%, platelets below 110,000 cells/mm3, creatinine, AST, ALT over 1.5 times upper limit of normal
- •At screening (must be within 21 days before study entry) any clinical evidence of HIV, hepatitis B, hepatitis C or active hepatitis A infection
- •Pregnancy (must have a negative serum pregnancy test within 21 days prior to the first dose of study drug, and urine pregnancy test must be negative on Study Day 0 before study entry)
- •History of cancer (except excision of basal cell carcinoma)
- •Any documented immunodeficiency
- •A history of prior administration of monoclonal antibodies or related proteins, with the exception of MEDI-507 (Note: prior recipients of MEDI-507 will require review and approval by the sponsor prior to entry)
- •Receipt of systemic retinoids, corticosteroids, cyclosporin A, methotrexate, phototherapy or coal tar treatment in the past 4 weeks
- •Use of topical therapy (except emollients) for psoriasis in the past 2 weeks (certain other over-the-counter products may be allowed with prior approval of the sponsor)
- •Receipt of any investigational drug therapy within 6 weeks before the first dose of study drug in this protocol (use of licensed agents for indications not listed in the package insert is permitted)
- •Current or planned participation in a research protocol in which an investigational agent or therapy may be administered
- •Nursing mother
- •Acute illness including infections
- •Clinical manifestations of significant end organ dysfunction or failure that may compromise the safety of the volunteer in the study
- •A known drug allergy or medical contraindication to ibuprofen
研究组 & 干预措施
未命名试验
干预措施: MEDI-507 (Drug)
结局指标
主要结局
Analyses of categorical data will be performed and analysis of continuous data will be performed using a one-way analysis of variance (ANOVA) with traetment group as a factor.
次要结局
- Percentage of subjects with at least 75% improvement and those with at least 50% improvement will be compared.
研究者
研究点 (3)
Loading locations...
相似试验
终止
2 期
Study of ASN51 in Adults With Early Alzheimer's DiseaseAlzheimer DiseaseNCT06677203Asceneuron S.A.123
已完成
2 期
Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use DisorderOpioid Use DisorderNCT06384157Indivior Inc.300
已完成
2 期
A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative ColitisColitis, UlcerativeNCT04613518Bristol-Myers Squibb38
终止
1 期
GI-270384 Study In Patients With Mild To Moderate Ulcerative ColitisUlcerative ColitisNCT00457171GlaxoSmithKline16
已完成
1 期
Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19HealthyChronic Stable IllnessNCT04519437Regeneron Pharmaceuticals974